PPD Launches Technology Portal to Improve Patient Retention in Clinical Trials - Applied Clinical Trials

ADVERTISEMENT

See our 2012 Buyers Guide Digital Edition.
Find Pharma Search Engine
PPD Launches Technology Portal to Improve Patient Retention in Clinical Trials

Source: Company News Release

PPD, Inc. announced it has launched an online portal linking clinical trial participants with biopharmaceutical companies, physicians, and healthcare resources to enhance patient connectivity and improve retention in clinical trials.

PPD PatientView is a secure online technology empowering clinical trial participants to view, share, and electronically archive medical information related to their illness, enabling them to play a more active role in managing their health and actively engaging them throughout the duration of a clinical trial.

"Regulatory agencies are requiring longer, more complex clinical studies, increasing the likelihood of patients leaving a clinical study before it's completed," said Mike Wilkinson, executive vice president and chief information officer for PPD. "The loss of patients during a trial can lead to increased costs and delay the trial's completion. PPD PatientView empowers patients by enabling better communication with the study team, better connectivity with study activities and better access to information about their individual disease."

PPD PatientView is customizable, allows patients online access to valuable health information, and is a convenient way to stay in continual contact with the trial registry and monitoring program. The portal leverages Microsoft HealthVault, a personal health application platform that lets consumers gather, store and share health information online.

PPD PatientView is a part of PPD® Adaptive Solutions, the suite of integrated technology solutions that PPD deploys to meet each client's needs in advancing their research initiatives. PPD and Microsoft have announced plans to jointly implement a technology solution to improve efficiency in managing U.S. Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) programs. PPD also was recognized on the 2010 InformationWeek 500, a list of the nation's most innovative users of business technology.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
90%
Borrow lightly from EMA's pathway program?
3%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here